Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab

Eye (Basingstoke)

Volumn 30, Issue 1, 2016, Pages 79-84

  Papakostas, T D ^a   Lim, L ^a   Van Zyl, T ^a   Miller, J B ^a   Modjtahedi, B S ^a   Andreoli, C M ^b   Wu, D ^a   Young, L H ^a   Kim, I K ^a   Vavvas, D G ^a   Esmaili, D D ^c   Husain, D ^a   Eliott, D ^a   Kim, L A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Harvard Vanguard Medical Association   (United States)

^c Retina Vitreous Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGED; ANATOMY; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MACULAR EDEMA; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY; TACHYPHYLAXIS; TREATMENT OUTCOME; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; RETINAL VEIN OCCLUSION; TREATMENT FAILURE; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84954285677     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.175     Document Type: Article

References (21)

1. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425-1433.
2. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol 2009; 127: 1101.
3. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460.
4. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133.e1.
5. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009; 93: 452-456.
6. Zhang H, Liu Z-L, Sun P, Gu F. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011; 27: 615-621.
7. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
8. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early vs late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 2013; 120: 1057-1063.
9. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
10. Korobelnik J-F, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the Phase 3 GALILEO Study. Ophthalmology 2014; 121: 202-208.
11. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121: 1414-1420.e1.
12. Eadie JA, Ip MS, Kulkarni AD. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina (Philadelphia, Pa) 2014; 34: 2439-2443.
13. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119: 1024-1032.
14. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013; 97: 278-284.
15. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155: 429-437.e7.
16. Ogura Y, Roider J, Korobelnik J-F, Holz FG, Simader C, Schmidt-Erfurth U et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the Phase 3 GALILEO Study. Am J Ophthalmol 2014; 158: 1032-1038.e2.
17. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS ONE 2008; 3: e3554.
18. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29-35.e2.
19. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22.e1.
20. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013; 156: 23-28.e2.
21. Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 2014; 121: 1059-1066.